Moderna
- Country
- πΊπΈUnited States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
- Conditions
- Human Metapneumovirus and Human Parainfluenza Infection
- Interventions
- Biological: PlaceboBiological: mRNA-1653
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT04144348
- Locations
- πΊπΈ
Central Research Associates Inc, Birmingham, Alabama, United States
πΊπΈMeridian Clinical Research, Norfolk, Nebraska, United States
πΊπΈClinical Research Prime, Idaho Falls, Idaho, United States
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
- Conditions
- Zika Virus
- Interventions
- Other: PlaceboBiological: mRNA-1893
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT04064905
- Locations
- πΊπΈ
Meridan Clinical Research, Omaha, Nebraska, United States
πΊπΈBenchmark Research, Fort Worth, Texas, United States
π΅π·Ponce School of Medicine - CAIMED Center, Ponce, Puerto Rico
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT03897881
- Locations
- πΊπΈ
University of Arizona, Tucson, Arizona, United States
πΊπΈCalifornia Pacific Medical Center Research Institute -CPMCRI, San Francisco, California, United States
πΊπΈAngeles Clinic and Research Institute, Santa Monica, California, United States
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
- Conditions
- Prevention of Chikungunya Virus Infection
- Interventions
- Other: PlaceboBiological: mRNA-1944
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03829384
- Locations
- πΊπΈ
PPD Phase 1 Clinical Research Unit, Austin, Texas, United States
Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic Acidemia
- Conditions
- Metabolism, Inborn ErrorsMethylmalonic Acidemia (MMA)
- Interventions
- Biological: mRNA-3704
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- ModernaTX, Inc.
- Registration Number
- NCT03810690
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
- Conditions
- Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC LymphomaDose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT03739931
- Locations
- πΊπΈ
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
πΊπΈProvidence St. John's Health Center, Santa Monica, California, United States
πΊπΈUniversity of Colorado Denver, Aurora, Colorado, United States
"The MaP Study": Mapping the Patient Journey in MMA and PA
- Conditions
- Propionic AcidemiaMethylmalonic Acidemia
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT03484767
- Locations
- πΊπΈ
Stanford Health Services, Stanford, California, United States
πΊπΈEmory Univeristy, Atlanta, Georgia, United States
πΊπΈAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
- Conditions
- Human Metapneumovirus and Human Parainfluenza Infection
- Interventions
- Other: PlaceboBiological: mRNA-1653
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT03392389
- Locations
- πΊπΈ
Meridian Clinical Research, LLC, Omaha, Nebraska, United States
πΊπΈBenchmark Research, Fort Worth, Texas, United States
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
- Conditions
- Cytomegalovirus Infection
- Interventions
- Biological: mRNA-1647Biological: mRNA-1443Other: Placebo
- First Posted Date
- 2017-12-22
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03382405
- Locations
- πΊπΈ
Research Centers of America, Hollywood, Florida, United States
πΊπΈAdvanced Clinical Research, Meridian, Idaho, United States
πΊπΈOptimal Research, Peoria, Illinois, United States
Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects
- Conditions
- Influenza
- Interventions
- Biological: VAL-339851Other: Placebo
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT03345043
- Locations
- πΊπΈ
Miami Research Associates, Miami, Florida, United States